These cells that express mutant KRAS undergo epigenetic alterations, e.g. hypermethylation in specific genes, followed by activation of WNT/B-catenin leading to proliferation, progression and 5-FU resistance in CRC [61]. The gene discussed is KRAS; the disease is colorectal carcinoma.